News

Home/News
News 2017-06-21T13:15:59+00:00
April 9, 2018
Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and ...
April 9, 2018
Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development of novel medicines to treat liver ...
April 9, 2018
VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority
TEL AVIV, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) today announced that it has been awarded a grant of 8.9 million New ...
April 9, 2018
TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
April 9, 2018
Casdin Capital to Become Shareholder in BioLife Solutions
BOTHELL, Wash., April 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the ...
April 9, 2018
Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will ...
April 9, 2018
MediWound’s NexoBrid® to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago
YAVNE, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
April 9, 2018
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
April 5, 2018
OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership
NANTES, France, April 05, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announced that it will host an audio/web conference to discuss its global immuno-oncology ...
April 5, 2018
AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease
Lausanne, Switzerland, April 5, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ...
April 5, 2018
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
AUSTIN, Texas, April 05, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
April 5, 2018
Rockwell Medical Announces Triferic Presentations at the 2018 National Kidney Foundation Spring Clinical Meetings
WIXOM, Mich., April 05, 2018 (GLOBE NEWSWIRE) --  Rockwell Medical, Inc. (RMTI), announced today that three Triferic abstracts have been selected for presentation at the National ...
April 4, 2018
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
INGELHEIM, Germany and NANTES, France, April 04, 2018 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics (Mnémo:OSE), a biotechnology company focused on the development of ...
April 4, 2018
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New ...
April 4, 2018
Windtree Therapeutics Announces Closing of $2.6 Million Private Placement
WARRINGTON, Pa., April 4, 2018 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it ...
April 4, 2018
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today reported key pipeline ...
April 4, 2018
Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development of novel medicines to treat liver ...
April 4, 2018
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
INGELHEIM, Germany and NANTES, France, April 04, 2018 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics (Mnémo:OSE), a biotechnology company focused on the development of ...
April 4, 2018
EDAP TMS SA : EDAP Reports First US Cohort Study Results of Focal HIFU Prostate Ablation Shows Promising Outcomes
LYON, FRANCE, AUSTIN, TX -- APRIL 3, 2018 - EDAP TMS (EDAP) today announced that preliminary results of the first U.S. clinical cohort study of ...
April 4, 2018
CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
MONMOUTH JUNCTION, N.J., April 4, 2018 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and ...
Page 5 of 70